Yunnan Baiyao, who was once known as the god of stock, has withdrawn from all secondary market securities investment, and this year will no longer conduct investment business.
Comprehensive Surging News, Securities Times, etc., a record of investor research disclosed on Wednesday (January 17), Yunnan Baiyao Group Co., Ltd.The balance of financial assets was 287 million yuan (RMB, the same below, about S $ 54 million), a decrease of 88.13%from the beginning of the year. The main reason was that in the third quarter, all Xiaomi Group and some fund investment held by the company.
Yunnan Baiyao shows that under the principles of further focusing on the main business and careful investment, the company has withdrawn from all secondary market securities investment in the third quarter of 2023, and will no longer carry out secondary market securities investment business in 2024.
In 2019, Yunnan Baiyao entered the investment market for the first time. With the holding of Kyushu Tong, Jacoben Research Pharmaceuticals, Red Tower Securities, China Antibody, and six bond funds, they reached 227 million yuan.The total profit of the year was 4.8%.
The next year, Yunnan Baiyao expanded its investment scope, adding positions, Xiaomi, Hengrui Pharmaceutical, Moutai, Yili, Chinese creatures, etc.At the end of 2020, Yunnan Baiyao's trading financial assets increased by 2.408 billion yuan compared with the previous year, allowing Yunnan Baiyao to get the name of the "stock god" of the A -share listed company.
But as a leading Chinese medicine stock in China, Yunnan Baiyao has attracted market attention many times for losses in recent years.In the two years of 2021 and 2022, Yunnan Baiyao lost more than 2.2 billion yuan due to the loss of stocks.
